First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Public ClinicalTrials.gov record NCT05099172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
Study identification
- NCT ID
- NCT05099172
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 370 participants
Conditions and interventions
Interventions
- BAY2927088_formulation A Drug
- BAY2927088_formulation B_1 Drug
- BAY2927088_formulation B_2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2021
- Primary completion
- Nov 29, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Apr 13, 2026
2021 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center at Banner Gateway Medical Center | Gilbert | Arizona | 85234 | — |
| City of Hope - Duarte Cancer Center | Duarte | California | 91010 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| The Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Dana-Farber Cancer Institute - Oncology Department | Boston | Massachusetts | 02215 | — |
| Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit | Detroit | Michigan | 48202 | — |
| NYU Langone Hospital - Long Island - Urology | Mineola | New York | 11501 | — |
| Tennessee Oncology - Nashville Centennial Clinic | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center - Texas Medical Center | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists, PC - Fairfax | Fairfax | Washington | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05099172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05099172 live on ClinicalTrials.gov.